A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Huelsmann, Peter M ^a   Hofmann, Andreas D ^a   Knoepfel, Stefanie A ^a   Popp, Jasmin ^a   Rauch, Pia ^a   Di Giallonardo, Francesca ^b   Danke, Christina ^a   Gueckel, Eva ^a   Schambach, Axel ^c   Wolff, Horst ^d   Metzner, Karin J ^a,b   Berens, Christian ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; APOPTOTIC PROTEINS; APPLIED SCIENCE; GENOMIC DNA; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; INFECTED CELLS; INFECTIOUS VIRUS; REGULATORY PROTEIN; SPECIFIC SUBSET; SUICIDE VECTORS; TRANSGENE EXPRESSION; VIRAL REPLICATION;

CELL DEATH; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; PROTEINS; VIRUSES;

DISEASES;

GENOMIC DNA; PROTEIN BID; REV PROTEIN; REV PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; REV PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS-1; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; SUICIDE GENE; VIRUS PARTICLE; VIRUS REPLICATION; FLOW CYTOMETRY; GENE VECTOR; GENETICS; HELA CELL; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY; SUICIDE TRANSGENE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CLONING, MOLECULAR; FLOW CYTOMETRY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HELA CELLS; HIV-1; HUMANS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 78651092348     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-4     Document Type: Article

References (63)

1. Han JH, Kushner SA, Yiu AP, Hsiang HL, Buch T, Waisman A, Bontempi B, Neve RL, Frankland PW, Josselyn SA. Selective erasure of a fear memory. Science 2009, 323:1492-1496. 10.1126/science.1164139, 19286560.
2. Du Pasquier D, Chesneau A, Ymlahi-Ouazzani Q, Boistel R, Pollet N, Ballagny C, Sachs LM, Demeneix B, Mazabraud A. tBid mediated activation of the mitochondrial death pathway leads to genetic ablation of the lens in Xenopus laevis. Genesis 2007, 45:1-10. 10.1002/dvg.20252, 17154276.
3. Lee P, Morley G, Huang Q, Fischer A, Seiler S, Horner JW, Factor S, Vaidya D, Jalife J, Fishman GI. Conditional lineage ablation to model human diseases. Proc Natl Acad Sci USA 1998, 95:11371-11376. 10.1073/pnas.95.19.11371, 21649, 9736743.
4. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007, 5:464-475. 10.1016/j.cmet.2007.05.001, 17550781.
5. Turner LS, Tsygankov AY, Henderson EE. StpC-based gene therapy targeting latent reservoirs of HIV-1. Antiviral Res 2006, 72:233-241. 10.1016/j.antiviral.2006.06.010, 16891001.
6. Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F, Bordignon C. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007, 15:1248-1252. 10.1038/sj.mt.6300190, 17505474.
7. Chu Y, Senghaas N, Köster RW, Wurst W, Kühn R. Novel caspase-suicide proteins for tamoxifen-inducible apoptosis. Genesis 2008, 46:530-536. 10.1002/dvg.20426, 18802959.
8. de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol 2008, 180:6365-6373.
9. Young J, Tang Z, Yu Q, Yu D, Wu Y. Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis. Retrovirology 2008, 5:36. 10.1186/1742-4690-5-36, 2391154, 18439272.
10. Kiuru M, Boyer JL, O'Connor TP, Crystal RG. Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 2009, 4:289-300. 10.1016/j.stem.2009.03.010, 19341619.
11. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996, 2:216-223. 10.1038/nm0296-216, 8574968.
12. Kerr DJ, Young LS, Searle PF, McNeish IA. Gene directed enzyme prodrug therapy for cancer. Adv Drug Deliv Rev 1997, 26:173-184. 10.1016/S0169-409X(97)00033-1, 10837541.
13. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009, 14:4517-4545. 10.3390/molecules14114517, 19924084.
14. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004, 116:205-219. 10.1016/S0092-8674(04)00046-7, 14744432.
15. Conradt B. Genetic control of programmed cell death during animal development. Annu Rev Genet 2009, 43:493-523. 10.1146/annurev.genet.42.110807.091533, 2806233, 19886811.
16. Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003, 63:6815-6824.
17. Del Gaizo Moore V, Letai A. Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push?. Adv Exp Med Biol 2008, 615:159-175. full_text, 18437895.
18. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med 1999, 5:29-33. 10.1038/4710, 9883836.
19. Carlotti F, Zaldumbide A, Martin P, Boulukos KE, Hoeben RC, Pognonec P. Development of an inducible suicide gene system based on human caspase 8. Cancer Gene Ther 2005, 12:627-639. 10.1038/sj.cgt.7700825, 15746943.
20. Yip KW, Li A, Li JH, Shi W, Chia MC, Rashid SA, Mocanu JD, Louie AV, Sanchez O, Huang D, et al. Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther 2004, 10:533-544. 10.1016/j.ymthe.2004.05.026, 15336653.
21. McCoubrie JE, Kendrick TS, Minchin RF. HIV LTR-dependent expression of Bax selectively induces apoptosis in Tat-positive cells. Biochem Biophys Res Commun 2004, 325:1459-1464. 10.1016/j.bbrc.2004.10.195, 15555592.
22. Garg H, Salcedo R, Trinchieri G, Blumenthal R. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther 2009,
23. Knott A, Drueppel L, Beyer T, Garke K, Berens C, Herrmann M, Hillen W. An optimized conditional suicide switch using doxycycline-dependent expression of human tBid. Cancer Biol Ther 2005, 4:532-536. 10.4161/cbt.4.5.1658, 15846082.
24. Kazhdan I, Long L, Montellano R, Cavazos DA, Marciniak RA. Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther 2006, 13:141-149. 10.1038/sj.cgt.7700867, 16110313.
25. Miao J, Chen GG, Chun SY, Yun JP, Chak EC, Ho RL, Lai PB. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. Int J Cancer 2006, 119:1985-1993. 10.1002/ijc.22040, 16708390.
26. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996, 10:2859-2869. 10.1101/gad.10.22.2859, 8918887.
27. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501. 10.1016/S0092-8674(00)81590-1, 9727492.
28. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998, 94:481-490. 10.1016/S0092-8674(00)81589-5, 9727491.
29. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299. 10.1016/S0140-6736(08)61113-7, 18657708.
30. Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005, 19:487-494. 10.1097/01.aids.0000171414.99409.fb, 15764854.
31. Adelson ME, Martinand-Mari C, Iacono KT, Muto NF, Suhadolnik RJ. Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur J Biochem 1999, 264:806-815. 10.1046/j.1432-1327.1999.00661.x, 10491127.
32. Hamouda T, McPhee R, Hsia SC, Read GS, Holland TC, King SR. Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. J Virol 1997, 71:5521-5527. 191794, 9188626.
33. Curiel TJ, Cook DR, Wang Y, Hahn BH, Ghosh SK, Harrison GS. Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene. Hum Gene Ther 1993, 4:741-747. 10.1089/hum.1993.4.6-741, 8186289.
34. Ragheb JA, Couture L, Mullen C, Ridgway A, Morgan RA. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev. Hum Gene Ther 1999, 10:103-112. 10.1089/10430349950019237, 10022535.
35. Agarwal S, Nikolai B, Yamaguchi T, Lech P, Somia NV. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther 2006, 14:555-563. 10.1016/j.ymthe.2006.03.025, 16814610.
36. Caruso M, Klatzmann D. Selective killing of CD4 + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci USA 1992, 89:182-186. 10.1073/pnas.89.1.182, 48200, 1346066.
37. Marcello A, Giaretta I. Inducible expression of herpes simplex virus thymidine kinase from a bicistronic HIV1 vector. Res Virol 1998, 149:419-431. 10.1016/S0923-2516(99)80010-7, 9923018.
38. Muesing MA, Smith DH, Capon DJ. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell 1987, 48:691-701. 10.1016/0092-8674(87)90247-9, 3643816.
39. Zapp ML, Green MR. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 1989, 342:714-716. 10.1038/342714a0, 2556643.
40. Wolff H, Brack-Werner R, Neumann M, Werner T, Schneider R. Integrated functional and bioinformatics approach for the identification and experimental verification of RNA signals: application to HIV-1 INS. Nucleic Acids Res 2003, 31:2839-2851. 10.1093/nar/gkg390, 156724, 12771211.
41. Wolkowicz R, Nolan GP. Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther 2005, 12:467-476. 10.1038/sj.gt.3302488, 15703764.
42. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol 2007, 25:1444-1454. 10.1038/nbt1367, 18066041.
43. Schambach A, Baum C. Clinical application of lentiviral vectors - concepts and practice. Curr Gene Ther 2008, 8:474-482. 10.2174/156652308786848049, 19075630.
44. Bednarik DP, Mosca JD, Raj NB, Pitha PM. Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. Proc Natl Acad Sci USA 1989, 86:4958-4962. 10.1073/pnas.86.13.4958, 297535, 2472636.
45. Wu Y, Beddall MH, Marsh JW. Rev-dependent lentiviral expression vector. Retrovirology 2007, 4:12. 10.1186/1742-4690-4-12, 1797186, 17286866.
46. Kramer-Hammerle S, Ceccherini-Silberstein F, Bickel C, Wolff H, Vincendeau M, Werner T, Erfle V, Brack-Werner R. Identification of a novel Rev-interacting cellular protein. BMC Cell Biol 2005, 6:20. 10.1186/1471-2121-6-20, 1097722, 15847701.
47. Wolff H, Hadian K, Ziegler M, Weierich C, Kramer-Hammerle S, Kleinschmidt A, Erfle V, Brack-Werner R. Analysis of the influence of subcellular localization of the HIV Rev protein on Rev-dependent gene expression by multi-fluorescence live-cell imaging. Exp Cell Res 2006, 312:443-456. 10.1016/j.yexcr.2005.11.020, 16368434.
48. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, Kleinschmidt A, Cepok S, Hemmer B, Durner J, Brack-Werner R. EASY-HIT: HIV Full-Replication Technology for Broad Discovery of Multiple Classes of HIV Inhibitors. Antimicrob Agents Chemother 2010, 54:5257-5268. 10.1128/AAC.00515-10, 20876377.
49. Madesh M, Antonsson B, Srinivasula SM, Alnemri ES, Hajnoczky G. Rapid kinetics of tBid-induced cytochrome c and Smac/DIABLO release and mitochondrial depolarization. J Biol Chem 2002, 277:5651-5659. 10.1074/jbc.M108171200, 11741882.
50. Shelton SN, Shawgo ME, Robertson JD. Cleavage of Bid by executioner caspases mediates feed forward amplification of mitochondrial outer membrane permeabilization during genotoxic stress-induced apoptosis in Jurkat cells. J Biol Chem 2009, 284:11247-11255. 10.1074/jbc.M809392200, 2670129, 19233849.
51. Rhee SS, Marsh JW. Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4. J Virol 1994, 68:5156-5163. 236459, 8035515.
52. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8:681-686.
53. Kabat D, Kozak SL, Wehrly K, Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994, 68:2570-2577. 236734, 8139036.
54. Mack M, Kleinschmidt A, Brühl H, Klier C, Nelson PJ, Cihak J, Plachý J, Stangassinger M, Erfle V, Schlöndorff D. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000, 6:769-775. 10.1038/77498, 10888925.
55. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM. The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997, 99:1546-1554. 10.1172/JCI119317, 507974, 9119998.
56. Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci USA 1991, 88:5011-5015. 10.1073/pnas.88.11.5011, 51797, 1711215.
57. Davis AJ, Li P, Burrell CJ. Kinetics of viral RNA synthesis following cell-to-cell transmission of human immunodeficiency virus type 1. J Gen Virol 1997, 78:1897-1906.
58. Pomerantz RJ, Seshamma T, Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 1992, 66:1809-1813. 240948, 1738210.
59. Nasioulas G, Zolotukhin AS, Tabernero C, Solomin L, Cunningham CP, Pavlakis GN, Felber BK. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994, 68:2986-2993. 236788, 8151769.
60. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem 2000, 275:21648-21652. 10.1074/jbc.M001083200, 10801801.
61. Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 2000, 290:1761-1765. 10.1126/science.290.5497.1761, 11099414.
62. Huelsmann PM, Rauch P, Allers K, John MJ, Metzner KJ. Inhibition of drug-resistant HIV-1 by RNA interference. Antiviral Res 2006, 69:1-8. 10.1016/j.antiviral.2005.10.001, 16290277.
63. McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol 1991, 65:852-860. 239825, 1898972.